Business
Enlivex Therapeutics Closes $16.75 Million Registered Direct Offering
Nes-Ziona, Israel, March 05, 2020 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a clinical-stage immunotherapy company, today announced the
About this update from Enlivex Ltd.
[{"type":"text","content":"Nes-Ziona, Israel, March 05, 2020 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a clinical-stage immunotherapy company, today announced the closing of its previously announced registered direct offering to certain accredited and healthcare-focused institutional investors, including Armistice Capital, of an aggregate of 2,093,750 ordinary shares of the Company and warrants to purchase up to an aggregate of 2,093,750 ordinary shares at a combined purchase price of $8.00 per share and associated warrant, for aggregate gross proceeds of $16.75 million. \n H.C. Wainwright & Co. acted as the exclusive placement agent for the offering. The warrants have an exercise price of $9.00 per ordinary share, an exercise period commencing immediately upon issuance and a term of two years from the issuance date. As part of the offering, the Company agreed to a customary lock-up period of 75 days following the offering. The Company intends to use the net proceeds from the offering for clinical, regulatory, manufacturing and research and development activities, potential acquisitions and in-licensing, as well as for working capital and other general corporate purposes. A shelf registration statement on Form F-3 (File No. 333-232009) relating to the securities offered in the registered direct offering described above was filed with the Securities and Exchange Commission (the “SEC”) on June 7, 2019 and declared effective by the SEC on June 21, 2019. The offering was made only by means of the written prospectus and prospectus supplement that form a part of such shelf registration statement. A final prospectus supplement and the accompanying prospectus related to the offering has been filed with the SEC and may be obtained for free by visiting EDGAR on the SEC website at www.sec.gov. Electronic copies of the final prospectus supplement and the accompanying prospectus relating to the offering may also be obtained by contacting H.C. Wainwright & Co., LLC, 430 Park Avenue, 3rd Floor, New York, NY 10022, or by calling (646) 975-6996 or by emailing [email protected]. This press release shall not constitute an offer to sell or the solicitation of an offer to buy the securities described herein or any other securities, nor shall there be any sale of the securities described herein or any other securities in any state or other jurisdiction i...